掌跖红斑感觉症 (PPE)，也称为手足综合征，是一种以炎症介导的手掌和手足底皮肤损伤为特征的疾病。个人防护用品限制了抗癌药物的成功治疗应用。然而，由于缺乏准确的体外和体内动物模型，在临床前研究期间识别这种毒性具有挑战性。因此，需要可靠的模型来在药物开发过程的早期检测这种毒性。在此，我们描述了使用体外皮肤外植体测定来评估传统 DXR、Doxil 参考上市药物 (RLD) 和两种通用聚乙二醇化脂质体 DXR 制剂引起炎症和皮肤损伤的能力。我们证明，传统 DXR 和 Doxil 的体外皮肤外植体测定模型获得的结果与临床数据相关。版权所有 © 2024。由 Elsevier Inc. 出版。

Palmar-plantar erythrodysesthesia (PPE), also known as hand and foot syndrome, is a condition characterized by inflammation-mediated damage to the skin on the palms and soles of the hands and feet. PPE limits the successful therapeutic applications of anticancer drugs. However, identifying this toxicity during preclinical studies is challenging due to the lack of accurate in vitro and in vivo animal-based models. Therefore, there is a need for reliable models that would allow the detection of this toxicity early during the drug development process. Herein, we describe the use of an in vitro skin explant assay to assess traditional DXR, Doxil reference listed drug (RLD) and two generic PEGylated liposomal DXR formulations for their abilities to cause inflammation and skin damage. We demonstrate that the results obtained with the in vitro skin explant assay model for traditional DXR and Doxil correlate with the clinical data.Copyright © 2024. Published by Elsevier Inc.